https://www.selleckchem.com/pr....oducts/nf-kb-activat
Risk stratification for localized renal cell carcinoma (RCC) relies heavily on retrospective models, limiting their generalizability to contemporary cohorts. To introduce a contemporary RCC prognostic model, developed using prospective, highly annotated data from a phase III adjuvant trial. The model utilizes outcome data from the ECOG-ACRIN 2805 (ASSURE) RCC trial. The primary outcome for the model is disease-free survival (DFS), with overall survival (OS) and early disease progression (EDP) as secondary outcomes. Model perfo